litlas
Log inCreate account

Timothy Iveson

Active 1993–2024

60
Papers
28,230
Citations
44
h-index
59
i10-index

Citations

Citations per year for Timothy Iveson1939: 2 citations1993: 1 citations1994: 1 citations1995: 4 citations1996: 4 citations1997: 1 citations1998: 11 citations1999: 9 citations2000: 15 citations2001: 35 citations2002: 44 citations2003: 53 citations2004: 66 citations2005: 87 citations2006: 82 citations2007: 104 citations2008: 114 citations2009: 102 citations2010: 154 citations2011: 145 citations2012: 96 citations2013: 157 citations2014: 179 citations2015: 162 citations2016: 155 citations2017: 178 citations2018: 141 citations2019: 689 citations2020: 818 citations2021: 804 citations2022: 706 citations2023: 495 citations2024: 944 citations2025: 407 citations2026: 23 citations1940–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,869 citing papers, 18.9% of this breakdownChina: 1,140 citing papers, 11.5% of this breakdownUnited Kingdom: 757 citing papers, 7.6% of this breakdownItaly: 633 citing papers, 6.4% of this breakdownGermany: 607 citing papers, 6.1% of this breakdownJapan: 594 citing papers, 6% of this breakdownFrance: 491 citing papers, 5% of this breakdownNetherlands: 414 citing papers, 4.2% of this breakdownSpain: 305 citing papers, 3.1% of this breakdownSouth Korea: 296 citing papers, 3% of this breakdownCanada: 243 citing papers, 2.4% of this breakdownAustralia: 201 citing papers, 2% of this breakdown
0%18.9%Other 23.8%

Institutions

Fields

  • Medicine83.3%
  • Biochemistry, Genetics and Molecular Biology11.1%
  • Immunology and Microbiology1.6%
  • Computer Science1.5%
  • Engineering0.6%
  • Materials Science0.5%
  • Other1.4%

Topics

  • Gastric Cancer Management and Outcomes9.2%
  • Cholangiocarcinoma and Gallbladder Cancer Studies8.5%
  • Colorectal Cancer Treatments and Studies6.3%
  • Esophageal Cancer Research and Treatment4.5%
  • Gallbladder and Bile Duct Disorders4.4%
  • Pancreatic and Hepatic Oncology Research4.3%
  • Other62.8%

Coauthors

All papers

Open in search
  1. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

    Authors: Juan W. Valle, Harpreet Wasan, Daniel H. Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Timothy Iveson, S. Hughes, Stephen P. Pereira, Sy Ha, John Bridgewater - New England Journal of Medicine 2010 cited by 4,404

  2. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: Guillem Argilés, Josep Tabernero, Roberto Labianca, Daniel Hochhauser, Ramón Salazar, Timothy Iveson, Pierre Laurent‐Puig, Philip Quirke, Takayuki Yoshino, Julien Taı̈eb, Erika Martinelli, Dirk Arnold - Annals of Oncology 2020 cited by 1,327

  3. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

    Authors: David Cunningham, William Allum, Sally Stenning, J N Thompson, Cornelis J.�H. van de Velde, M. Nicolson, J.H. Scarffe, F. Lofts, Stephen Falk, Timothy Iveson, David B. Smith, Ruth E. Langley, Monica Verma, Simon Weeden, Yu Jo Chua - New England Journal of Medicine 2006 cited by 6,362

  4. Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study

    Authors: Sophia J. Wagner, Daniel Reisenbüchler, Nicholas P. West, Jan Niehues, Jiefu Zhu, Sebastian Foersch, Gregory Patrick Veldhuizen, Philip Quirke, Heike I. Grabsch, Piet A. van den Brandt, Gordon Hutchins, Susan D. Richman, Tanwei Yuan, Rupert Langer, Josien C.A. Jenniskens, Kelly Offermans, Wolfram Mueller, Richard Gray, Stephen B. Gruber, Joel K. Greenson, Gad Rennert, Joseph D. Bonner, Daniel Schmolze, Jitendra Jonnagaddala, Nicholas J. Hawkins, Robyn L. Ward, Dion Morton, Michel Seymour, Laura Magill, Marta Nowak, Jennifer Hay, Viktor H. Koelzer, David N. Church, David N. Church, Enric Domingo, Joanne Edwards, Bengt Glimelius, Ismail Gögenür, Andrea Harkin, Jen Hay, Timothy Iveson, Emma Jaeger, Caroline Kelly, Rachel Kerr, Noori Maka, Hannah Morgan, Karin A. Oien, Clare Orange, Claire Palles, Campbell S.D. Roxburgh, Owen J. Sansom, Mark Saunders, Ian Tomlinson, Christian Matek, Carol Geppert, Chaolong Peng, Cheng Zhi, Xiaoming Ouyang, Jacqueline A. James, Maurice B. Loughrey, Manuel Salto‐Tellez, Hermann Brenner, Michael Hoffmeister, Daniel Truhn, Julia A. Schnabel, Melanie Boxberg, Tingying Peng, Jakob Nikolas Kather - Cancer Cell 2023 cited by 247

  5. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

    Authors: John N Primrose, Richard Fox, Daniel H. Palmer, Hassan Malik, Rajendra Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones, Harpreet Wasan, Paul J. Ross, Lucy Wall, Jonathan Wadsley, JEFF EVANS, Deborah Stocken, Raaj Praseedom, Yuk Ting, Brian R Davidson, John P. Neoptolemos, Timothy Iveson, James Raftery, Shihua Zhu, David Cunningham, O. James Garden, Clive Stubbs, Juan W. Valle, John Bridgewater, John Primrose, RP Fox, Helen Morement, Oscar S.H. Chan, C. Rees, Ma Yt, Tamas Hickish, Stephen Falk, Meg Finch-Jones, Ian Pope, Pippa Corrie, Tom Crosby, S. Sothi, K Sharkland, Douglas Adamson, Lucy Wall, JEFF EVANS, John Dent, U. Hombaiah, Chinenye Iwuji, Alan Anthoney, John Bridgewater, David Cunningham, Roopinder Gillmore, Paul J. Ross, S. Slater, Harpreet Wasan, Jill Waters, Juan W. Valle, Daniel H. Palmer, Hafiz Malik, John P. Neoptolemos, Olusola Olusesan Faluyi, Kate Sumpter, U. Dernedde, S Maduhusudan, G. Cogill, Caroline Archer, Timothy Iveson, Jonathan Wadsley, Suzanne Darby, Mike Peterson, AA Mukhtar, JG Thorpe, Adrian C Bateman, D. Tsang, S. Cummins, L. Nolan, Éric Beaumont, Rajendra Prasad, D. Mirza, Deborah Stocken, Raaj Praseedom, Brian R Davidson, James Raftery, Shihua Zhu, James Garden, C Stubbs, Fareeda Y. Coxon - The Lancet Oncology 2019 cited by 1,228

  6. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

    Authors: Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Paul J. Ross, Yuk Ting, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Timothy Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David J. Ryder, John Ramage, Linda Davies, John Bridgewater, Juan W. Valle - The Lancet Oncology 2021 cited by 749

  7. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

    Authors: Axel Grothey, Alberto Sobrero, Anthony F. Shields, Takayuki Yoshino, James Paul, Julien Taı̈eb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Déwi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Jeffrey P. Meyers, Lindsay A. Renfro, Donna Niedzwiecki, Toshiaki Watanabe, Valter Torri, Mark Saunders, Daniel J. Sargent, Thierry André, Timothy Iveson - New England Journal of Medicine 2018 cited by 1,126

  8. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

    Authors: David Cunningham, Naureen Starling, Sheela Rao, Timothy Iveson, M. Nicolson, Fareeda Y. Coxon, Gary Middleton, Francis Daniel, J. Oates, A. Norman - New England Journal of Medicine 2008 cited by 2,312

  9. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

    Authors: J-Y Douillard, David Cunningham, AD Roth, Matilde Navarro, RD James, Petr Karásek, P Jandı́k, Timothy Iveson, J Carmichael, May Alakl, G. Gruia, Lucile Awad, P Rougier - The Lancet 2000 cited by 3,279

  10. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

    Authors: Thierry André, Jeffrey A. Meyerhardt, Timothy Iveson, Alberto Sobrero, Takayuki Yoshino, Ioannis Souglakos, Axel Grothey, Donna Niedzwiecki, Mark Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Déwi Vernerey, Jeffrey P. Meyers, Andrea Harkin, Valter Torri, Eiji Oki, Vassilis Georgoulias, Julien Taı̈eb, Anthony F. Shields, Qian Shi - The Lancet Oncology 2020 cited by 298

  11. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

    Authors: Gary Middleton, Paul Silcocks, Trevor F. Cox, Juan W. Valle, Jonathan Wadsley, David Propper, Fareeda Y. Coxon, Paul J. Ross, Srinivasan Madhusudan, Tom Roques, David Cunningham, Stephen Falk, Nick Wadd, Mark Harrison, Pippa Corrie, Timothy Iveson, Angus Robinson, Karen McAdam, Martin Eatock, JEFF EVANS, Caroline Archer, Tamas Hickish, Angel Garcia-Alonso, M. Nicolson, William P. Steward, Alan Anthoney, William Greenhalf, Victoria Shaw, Eithne Costello, Dean J. Naisbitt, Charlotte Rawcliffe, Gemma Nanson, John P. Neoptolemos - The Lancet Oncology 2014 cited by 374

  12. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

    Authors: Joris van de Haar, Xuhui Ma, Salo Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul J. Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, N. Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F.A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri - Nature Medicine 2023 cited by 84

  13. Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

    Authors: Elisa Fontana, Jeff Meyers, Alberto Sobrero, Timothy Iveson, Anthony F. Shields, Julien Taieb, Takayuki Yoshino, Ioannis Souglakos, Elizabeth C. Smyth, Florian Lordick, Markus Moehler, Anne Giraut, Andrea Harkin, Roberto Labianca, Jeffrey Meyerhardt, Thierry André, Ioannis Boukovinas, Sara Lonardi, Mark Saunders, Dewi Vernerey, Eiji Oki, Vassilis Georgoulias, Irit Ben-Aharon, Qian Shi - Journal of Clinical Oncology 2021 cited by 104

  14. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors

    Authors: Kathryn A.F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang‐Yu Lian, Sara Samir Foad Al-Badran, Jean A. Quinn, Assya Legrini, Jitwadee Inthagard, Peter Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A. Gillespie, Megan L. Mills, Aula Ammar, Jennifer Hay, Ditte K. Andersen, Colin Nixon, Selma Rebus, David K. Chang, Caroline Kelly, Andrea Harkin, Janet Graham, David N. Church, Ian D. Tomlinson, Mark Saunders, Timothy Iveson, Tamsin R.M. Lannagan, René Jackstadt, Noori Maka, Paul G. Horgan, Campbell S.D. Roxburgh, Owen J. Sansom, Donald C. McMillan, Colin W. Steele, Nigel B. Jamieson, James H. Park, Antonia K. Roseweir, Joanne Edwards - Journal of Experimental & Clinical Cancer Research 2024 cited by 45

  15. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

    Authors: Tom Waddell, Ian Chau, David Cunningham, David González de Castro, Alicia Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley, David Ferry, Wasat Mansoor, Tom Crosby, Fareeda Y. Coxon, David A. Smith, Justin S. Waters, Timothy Iveson, Stephen Falk, Sarah Slater, Clare Peckitt, Yolanda Barbáchano - The Lancet Oncology 2013 cited by 728

  16. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

    Authors: John Bridgewater, S. Pugh, Tom Maishman, Zina Eminton, J. M. MELLOR, Amy Whitehead, Louise Stanton, M Radford, Andrea Corkhill, Gareth Griffiths, Stephen Falk, Juan W. Valle, Derek O’Reilly, Ajith K. Siriwardena, Joanne Hornbuckle, Myrddin Rees, Timothy Iveson, Tamas Hickish, O. James Garden, David Cunningham, Tim Maughan, John N Primrose, Alaaeldin Shablack, Ann O’Callaghan, Anne Marie Moody, Alex Allen, A. Brewster, Alison Brown, Astrid Mayer, Brian R Davidson, Chan Ton, Charles Wilson, C. Lowdell, Charlotte Rees, Christopher Baughan, Clare Barlow, Colin Purcell, David Smith, David Tsang, Ewan Brown, Georgina Walker, Hassan Malik, Iain Cameron, Luke Nolan, Marcia Hall, Marjorie Tomlinson, Mark Hill, Mark Peterson, Meg Finch-Jones, Nagappan Kumar, N D Karanjia, Nasim Ali, Nigel Heaton, Nua Chan Ton, Paul J. Ross, Raaj Praseedom, Robert Thomas, Sally Clive, Sarah Slater, Sarah Smith, Satvinder Mudan, Satya Bhattacharya, Sharadah Essapen, Sherif Raouf, Stephen W. Fenwick, Susan Cleator, Tom Diamond, Vanessa Potter - The Lancet Oncology 2020 cited by 239

  17. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

    Authors: Timothy Iveson, Alberto Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang‐Shu Ou, Jeffrey P. Meyers, Qian Shi, Axel Grothey, Mark Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels Henrik Holländer, Fabio Galli, Kentaro Yamazaki, Vassilis Georgoulias, Rachel Kerr, Eiji Oki, Sara Lonardi, Andrea Harkin, Gerardo Rosati, James Paul - Journal of Clinical Oncology 2021 cited by 104

  18. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

    Authors: John Primrose, Stephen Falk, Meg Finch-Jones, Juan W. Valle, Derek O’Reilly, Ajith K. Siriwardena, Joanne Hornbuckle, Mark Peterson, Myrddin Rees, Timothy Iveson, Tamas Hickish, Rachel Butler, Louise Stanton, Elizabeth Dixon, Louisa Little, Megan Bowers, S. Pugh, O. James Garden, David Cunningham, Tim Maughan, John Bridgewater - The Lancet Oncology 2014 cited by 433

  19. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

    Authors: Timothy Iveson, Rachel Kerr, Mark Saunders, Jim Cassidy, Niels Henrik Holländer, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Claire Scudder, Kathleen Boyd, Andrew Briggs, Ashita Waterston, Louise Medley, Charles B. Wilson, Richard Ellis, Sharadah Essapen, A.S. Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet Wasan, James Paul - The Lancet Oncology 2018 cited by 188

  20. A new prognostic and predictive tool for shared decision making in stage III colon cancer

    Authors: Alberto Sobrero, Alberto Puccini, Qian Shi, Axel Grothey, Thierry André, Anthony F. Shields, Ioannis Souglakos, Takayuki Yoshino, Timothy Iveson, Marcello Ceppi, Paolo Bruzzi - European Journal of Cancer 2020 cited by 69

  21. NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.

    Authors: Kai‐Keen Shiu, Yanrong Jiang, Mark Saunders, Jenny F. Seligmann, Timothy Iveson, Richard H. Wilson, Janet Graham, Khurum Khan, Anna-Maria Militello, Sandra Irvine, Temi Adedoyin, Rubina Begum, Reshma Bhat, William Wilson, Andrew Plumb, Austin Obichere, Manuel Rodriguez‐Justo, Marnix Jansen - Journal of Clinical Oncology 2024 cited by 33

  22. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

    Authors: Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony F. Shields, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Frank A. Sinicrope, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A. Meyerhardt, Thierry André, Demetris Papamichael, Julien Taı̈eb - Journal of Clinical Oncology 2022 cited by 50

  23. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

    Authors: Lennard Y. W. Lee, Thomas Starkey, Maria C. Ionescu, Martin Little, Michaël Tilby, Arvind Tripathy, Hayley McKenzie, Youssra Al-Hajji, Matthew Barnard, Liza Benny, Alexander Burnett, Emma Cattell, Jackie Charman, James J. Clark, Sam Khan, Q. Ghafoor, George Illsley, Catherine Harper‐Wynne, Rosie Hattersley, Alvin Lee, Pauline Leonard, Justin K. H. Liu, Emma Kinloch, Emily Lam, Gillian Murphy, Malcolm Rhodes, Kate Robinson, Matthew Pang, Jennifer Pascoe, James R. Platt, Vanessa Potter, Amelia Randle, Anne Rigg, Tim Robinson, Tom Roques, René L. Roux, Stefan Rozmanowski, Mark Tuthill, Isabella Watts, Sarah Williams, Timothy Iveson, Siow Ming Lee, Gary Middleton, Mark R. Middleton, Andrew Protheroe, Matthew W. Fittall, Tom Fowler, Peter Johnson - The Lancet Oncology 2022 cited by 96

  24. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial

    Authors: Nalinie Joharatnam‐Hogan, Fay Cafferty, Richard Hubner, Daniel Swinson, Sharmila Sothi, Kamalnayan Gupta, Stephen Falk, Kinnari Patel, Nicola Warner, Victoria Kunene, Sam Rowley, Komel Khabra, Tim Underwood, Janusz Jankowski, John Bridgewater, Anne Crossley, Verity Henson, Lindy Berkman, Duncan C. Gilbert, Howard Kynaston, Alistair Ring, David Cameron, Farhat V N Din, Janet Graham, Timothy Iveson, Richard Adams, Anne Thomas, Richard H. Wilson, C.S. Pramesh, Ruth E. Langley, John Burn, Sue Campbell, Lisa Capaldi, Yvonne Carse, Durga Gadgil, Arnold Goldman, Sudeep Gupta, Gregory Leonard, Mairead MacKenzie, Mahesh Parmar, Carlo Patrono, Russell Petty, Peter M. Rothwell, R. Steele - ˜The œLancet. Gastroenterology & hepatology 2019 cited by 65